Research Foci

My research has focused primarily on improving health outcomes in patients with psychiatric disorders.  This has included predicting and preventing side effects as well as drug-drug interactions; the effects that various drugs have on certain proteins such as P-glycoprotein which can increase or decrease the available drug at target sites; and pharmacogenomics which identifies genetic mutations that can effect a drugs ability to function.


Below includes a sample of original research and review articles from the past ten years.

Bachmeier C, Levin GM, Beaulieu-Abdelahad D, Reed J, Mullan M. Effect of venlafaxine and desvenlafaxine on drug efflux protein expression and biodistribution in vivo. J Pharm Sci 2013:102; 3838-3842.

Trendler A, Levin GM. Summary of 2012 Cochrane Collaboration meta-analysis Covering Newer Generation Antidepressants for Depressive Disorders in Children and Adolescents. Ment Health Clin. 2013;2(11):79.

Pulsipher J, Levin GM. The Use of Second Generation Antipsychotics in Children and Adolescents with Bipolar Disorder and Schizophrenia: A Summary of the AHRQ Comparative Effectiveness Review. Ment Health Clin. 2013;2(11):69.

Levin GM. P-glycoprotein: Why this drug transporter may be clinically important. Current Psychiatry 2012;11:38-40.

Bachmeier CJ, Beaulieu-Abdelahad D, Ganey NJ, Mullan MJ, Levin GM. Induction of Drug Efflux Protein Expression by Venlafaxine but not Desvenlafaxine. Biopharmaceutics and Drug Disposition 2011:32; 233-244.

Levin GM, Bowles TM, Ehret MJ, Langaee T, Tan JY, Tan JY, Johnson JA,Millard WJ.  Assessment of Human Serotonin 1A Receptor Polymorphisms and SSRI Responsiveness. Molecular Diagnosis and Therapy 2007:11;155-160.

Ehret MJ, Levin GM, Narasimhan M, and Rathinavelu A.Venlafaxine Induces P-glycoprotein in Human Caco-2 Cells. Human Psychopharmacology 2007;22:49-53.